Bégué P
Service de pédiatrie et de pathologie infectieuse, hôpital Trousseau, Paris, France.
Arch Pediatr. 1998;5 Suppl 3:296S-301S. doi: 10.1016/s0929-693x(98)80153-x.
Antimicrobial therapy for pyelonephritis in children must quickly eradicate the bacterial infection and prevent scars in renal parenchyma. Escherichia coli (E Coli) is found in about 90% of cases of acute pyelonephritis in outpatients, 40% of E coli being ampicillin-resistant. The present effective antibiotics are: 3rd-generation cephalosporines, amoxicillin-clavulanic acid association, and aminoglycosides. In the literature therapeutical guides are divergent concerning the route of administration (oral or i.v.), mono or bitherapy, the duration of the treatment (usually for 10 days), and the need for hospitalisation. The criteria for choice are risk factors such as: very young age (< 6 months), fever with toxic symptoms, vomiting, dehydration, uropathy, and poor compliance. There are few long term studies which compare two, therapeutic regimens and no evaluation of the frequency of consequent chronic pyelonephritis in adult age has taken place. Recent data suggest that an oral sequential treatment may permit a shorter hospital stage. The trend is chiefly to do bona fide recommendations more than elaboration of a true consensus.
儿童肾盂肾炎的抗菌治疗必须迅速根除细菌感染并防止肾实质形成瘢痕。门诊急性肾盂肾炎病例中约90%可发现大肠杆菌,其中40%的大肠杆菌对氨苄西林耐药。目前有效的抗生素有:第三代头孢菌素、阿莫西林 - 克拉维酸合剂和氨基糖苷类。文献中的治疗指南在给药途径(口服或静脉注射)、单药治疗或联合治疗、治疗持续时间(通常为10天)以及住院需求方面存在分歧。选择标准是危险因素,如:年龄很小(<6个月)、伴有中毒症状的发热、呕吐、脱水、泌尿系统疾病以及依从性差。很少有长期研究比较两种治疗方案,也没有对成年后患慢性肾盂肾炎的频率进行评估。最近的数据表明,口服序贯治疗可能会缩短住院时间。目前的趋势主要是做出善意的建议,而不是达成真正的共识。